Literature DB >> 9834108

Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection.

T Hussell1, A Georgiou, T E Sparer, S Matthews, P Pala, P J Openshaw.   

Abstract

In BALB/c mice, sensitization with the attachment protein (G) of respiratory syncytial virus (RSV) leads to CD4+ T cell-mediated lung eosinophilia during subsequent challenge with RSV. To determine the host genetic influences on this model of lung eosinophilia, we tested 15 different inbred mouse strains. Eosinophilia developed in all H-2d (BALB/c, DBA/2n, and B10.D2), but not in H-2k (CBA/Ca, CBA/J, C3H, BALB.K, or B10.BR) mouse strains. Among H-2b mice, 129 and BALB.B developed eosinophilia, whereas C57BL/6 and C57BL/10 did not. Testing first generation crosses between sensitive and resistant strains showed that eosinophilia developed in all H-2dxk (n = 5), irrespective of background genes, but not in H-2dxb (n = 2) mice. In vivo depletion of CD8+ T cells or IFN-gamma rendered C57BL/6, but not BALB.K mice, susceptible to eosinophilia. Analysis of B10 recombinant mice showed that the Dd allele (in B10.A(5R) mice) prevented CD8+ T cell accumulation in the lung, resulting in intense lung eosinophilia. However, the Db allele (in B10.A(2R) and B10.A(4R) mice) supported CD8+ T cell expansion and prevented eosinophilia. Intracellular cytokine staining showed that lung eosinophilia correlated with reduced IFN-gamma and increased IL-10 expression in lung T cells. These results are compatible with the unifying model that Th2 cells mediate the disease but can be inhibited by CD8+ T cells secreting IFN-gamma. Our findings have important implications for the development of protective, nonpathogenic vaccines for RSV disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9834108

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Analysis of recombinant mycobacteria as T helper type 1 vaccines in an allergy challenge model.

Authors:  R Janssen; A Kruisselbrink; L Hoogteijling; J R Lamb; D B Young; J E Thole
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

2.  Lactation-Based Maternal Educational Immunity Crosses MHC Class I Barriers and Can Impart Th1 Immunity to Th2-Biased Recipients.

Authors:  Mrinal K Ghosh; H Konrad Muller; Ameae M Walker
Journal:  J Immunol       Date:  2017-07-26       Impact factor: 5.422

Review 3.  New insights for development of a safe and protective RSV vaccine.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Kari Ann Shirey; Gregory A Prince; Stefanie N Vogel
Journal:  Hum Vaccin       Date:  2010-06-01

4.  Gene expression differences in lungs of mice during secondary immune responses to respiratory syncytial virus infection.

Authors:  Annemieke Schuurhof; Louis Bont; Jeroen L A Pennings; Hennie M Hodemaekers; Piet W Wester; Annemarie Buisman; Lia C G H de Rond; Myra N Widjojoatmodjo; Willem Luytjes; Jan L L Kimpen; Riny Janssen
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 5.  Vaccines for the common cold.

Authors:  Daniel Simancas-Racines; Juan Va Franco; Claudia V Guerra; Maria L Felix; Ricardo Hidalgo; Maria José Martinez-Zapata
Journal:  Cochrane Database Syst Rev       Date:  2017-05-18

6.  Respiratory virus-induced regulation of asthma-like responses in mice depends upon CD8 T cells and interferon-gamma production.

Authors:  Joost J Smit; Louis Boon; Nicholas W Lukacs
Journal:  Am J Pathol       Date:  2007-11-08       Impact factor: 4.307

7.  Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus.

Authors:  L M Haynes; D D Moore; E A Kurt-Jones; R W Finberg; L J Anderson; R A Tripp
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression.

Authors:  Guillermina A Melendi; Scott J Hoffman; Ruth A Karron; Pablo M Irusta; Federico R Laham; Alison Humbles; Brian Schofield; Chien-Hsiung Pan; Richard Rabold; Bhagvanji Thumar; Adeep Thumar; Norma P Gerard; Wayne Mitzner; Scott R Barnum; Craig Gerard; Steven R Kleeberger; Fernando P Polack
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

9.  Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination.

Authors:  Elaine M Castilow; Steven M Varga
Journal:  Future Virol       Date:  2008       Impact factor: 1.831

10.  Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.

Authors:  Teresa R Johnson; Michael N Teng; Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.